Enigma Diagnostics specializes in advanced molecular diagnostics, which play a crucial role in the timely and accurate identification of diseases. Their technology emphasizes precision medicine, allowing healthcare professionals to tailor treatments based on individual genetic profiles. This approach enhances the effectiveness of therapies and supports the development of targeted interventions. Enigma's offerings include innovative techniques such as liquid biopsies, which enable non-invasive detection of circulating tumor DNA, and next-generation sequencing (NGS), which facilitates comprehensive genetic testing. These advancements not only improve disease diagnosis but also aid in monitoring disease progression and treatment responses.

Additionally, Enigma Diagnostics is committed to optimizing the use of their tests through best practices in sample collection, quality control, and data analysis. They advocate for collaboration among clinicians, laboratory staff, and bioinformaticians to ensure seamless integration of molecular diagnostics into patient care. The company also highlights the importance of staying informed about the latest developments in molecular diagnostics to maximize the benefits for patients. Overall, Enigma Diagnostics is at the forefront of innovation in the field, contributing significantly to personalized medicine and enhancing healthcare outcomes through their reliable testing solutions.

United Kingdom

Enigma Diagnostics is a
 PCR-based testing out of the laboratory with a range of simple-to-use products.

Enigma Diagnostics

Company Details